Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

ORPHENADRINE CITRATE

All injection strengths: not a benefit

Other products in the same Health Canada class (M03B) — coverage varies; not interchangeable

  • Baclofen (Lioresal Intrathecal): general benefit, Not a benefit
  • Cyclobenzaprine (Flexeril): not a benefit
  • Tizanidine (Zanaflex): not a benefit

Norflex · DIN 01966162 · 60mg/2mL · injection solution-2mL Pk

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-07-30 — choose a marketed DIN from the same-category list.Discontinued 2014-07-30 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2014-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2014-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Norflex · DIN 01966162 Manufacturer: 3M Pharmaceuticals, Division 3M Canada Inc.; listing date 1996-10-01 Health Canada: Cancelled post market since 2014-07-30 · brand NORFLEX · ATC M03BC01 ORPHENADRINE (CITRATE) · form Liquid · route Intravenous, Intramuscular · ingredients ORPHENADRINE CITRATE 30 MG/ML · company Valeant canada lp / valeant canada s.e.c. · schedule Ethical
Check this DIN again · Health Canada product record

Norflex: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14003 · Verify on the e-Formulary ↗ (DIN 01966162)

Source record
DIN 01966162: Norflex Raw flags: notABenefit=Y, sec3=Y Item: 122000007; group id 243; item number 0434; lccId None; manufacturer id MMH Source form: Inj Sol-2mL Pk; strength: 60mg/2mL Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01966162 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14003
Interchangeable products
Orphenadrine · DIN 02229731 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=01966162
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2014-07-30 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (12:20 Skeletal Muscle Relaxants) and how they are covered

Matched class: 12:20 Skeletal Muscle Relaxants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DANTROLENE SODIUM Some products covered without a code (check the product listing): BACLOFEN 12:20 Skeletal Muscle Relaxants

BACLOFEN

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (12), General benefit (16) · strengths: 2mg/mL, 0.05mg/mL, 0.5mg/mL, 10mg, 20mg · Inj Sol (Preservative-Free), Inj Sol-1mL Pk (Preservative-Free), Inj Sol-20mL Pk (Preservative-Free), Tab

CYCLOBENZAPRINE HCL

· 12 products · Listed, not a benefit · strengths: 10mg · Tab

TIZANIDINE HCL

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 4mg · Tab

DANTROLENE SODIUM

· 1 products · General benefit · strengths: 25mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 12:20
Full class listing Related classes: 12:04 Parasympathomimetic (Cholinergic) Agents, 12:08 Parasympatholytic (Cholinergic Blocking) Agents, 12:12 Sympathomimetic (Adrenergic) Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found

Other review policies

For Norflex: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026